Gritstone Oncology is a privately-held cancer immunotherapy company developing next-generation personalized cancer therapeutics. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and deep financial backing to tackle fundamental challenges at the intersection of cancer genomics, immunology, and immunotherapy design. The company's initial goal is to identify and deploy therapeutic neo-antigens from individual patients' tumors to develop novel treatments for lung cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/20/15 | $102,000,000 | Series A |
Casdin Capital Clarus Ventures Frazier Healthcare Redmile Group The Column Group Transformational Healthcare Opportunity Versant Ventures | undisclosed |
| 09/07/17 | $92,700,000 | Series B |
Alexandria Venture Investments Clarus Funds Frazier Healthcare Lilly Asia Ventures  The Column Group Trinitas Capital Versant Ventures | undisclosed |
